Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update

European Annals of Allergy and Clinical Immunology

Volumn 42, Issue 4, 2010, Pages 135-140

  D'Amato, G ^a   Perticone, M ^b   Bucchioni, E ^b   Salzillo, A ^a   D'Amato, M ^c   Liccardi, G ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b Medical Advisor Infectious Diseases and Hepatology   (Italy)

^c Department of Respiratory Diseases   (Italy)

Author keywords

Airways hyperresponsiveness; Allergic asthma; Allergic respiratory diseases; Anti IgE therapy; Monoclonal anti IgE antibody; Omalizumab; Therapy of asthma

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E; OMALIZUMAB;

ADOLESCENT DISEASE; ADULT DISEASE; ALLERGIC ASTHMA; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; MORTALITY; QUALITY OF LIFE; REVIEW;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ASTHMA; DISEASE PROGRESSION; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULIN E; IMMUNOTHERAPY; QUALITY OF LIFE;

EID: 77955487167     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Loddenkemper R, Gibson GJ, Sibille Y eds. European Lung White Book. The first comprehensive survey on respiratory health in Europe. European Respiratory Society (ERS). ERSJ 2003.
2. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 468-78.
3. Rabe KF, Adachi M, Lai CK, et al.Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40-7.
4. D'Amato G, Cecchi L, D'Amato M, Liccardi G, Holgate ST. Urban air pollution and climate change as environmental risk factors of respiratory allergy: an update. J Invest Allergol Clin Immunol 2010; 20: 95-102.
5. Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999; 402: B1-17.
6. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368 (9537): 804-13.
7. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Resp J 2003; 22: 470-7.
8. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119: 405-13.
9. Busse WW, Coffman RL, Gelfand EW, Kay AB, Rosenwasser LJ. Mechanisms of persistent airway inflammation in asthma. A role for T cells and T-cell products. Am J Respir Crit Care Med 1995; 152: 388-93.
10. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003; 112: 252-62.
11. Wenzel SE, Westcott JY, Larsen GL. Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J Allergy Clin Immunol 1991; 87: 540-8.
12. Hollowaj JA, Holgate ST, Semper AE. Expression of the high-affinity IgE receptor on peripheral blood dendritic cells: differential binding of IgE in atopic asthma. J Allergy Clin Immunol 2001; 107: 1009-18.
13. National Institutes of Health/National Heart Lung and Blood Institute (NHLBI). Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report March 2004. Bethesda, MD
14. Van Ganse E, Laforest L, Pietri G, et al. Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J 2002; 20: 260-7
15. Crane J, Pearce N, Burgess C, et al. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol 1992; 21: 737-44.
16. Serra-Batles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree od severity. Eur Respir J 1998; 12: 1322-6.
17. Boulet L-P, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835-40.
18. Godard P, Chanez L, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 18: 61-7.
19. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828-34.
20. Fahy JV. The anti-IgE treatment strategy for asthma. In: Yeadon M, Diamant Z, eds. New and Exploratory Therapeutic Agents for Asthma: Lung Biology in Health and Disease. Marcel Dekker; 2000: 329-42.
21. Chang TW. The pharmacological basis of anti-IgE therapy. Nature Biotechnology 2000; 18: 157-63.
22. D'Amato G. Oldani V, Donner C. Treating atopic asthma with the anti-IgE monoclonal antibody. Monaldi Arch Chest Dis 2002; 57 (2): 117-9.
23. D'Amato G Therapy of allergic bronchial asthma with anti-IgE monoclonal antibody. Expert Opinion on Biological Therapy 2003; 3: 371-6.
24. D'Amato G, Liccardi G, Noschese P, Salzillo A, Cazzola M. Anti-IgE Monoclonal Antibody (Omalizumab) in the Treatment of Atopic Asthma and Allergic Respiratory Diseases. Current Drug Targets Inflammation & Allergy 2004; 3 (3).
25. Kuehr J, Brauburger J, Zielen S, Schauer U, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 274-80.
26. Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001; 17: 233-40.
27. D'Amato G. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. Eur J Pharmacol 2006; 533: 302-07.
28. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254-61.
29. Busse W, Coren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-90
30. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108 (2): 36-45.
31. Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20: 73-8.
32. Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002; 20: 1088-94.
33. Buhl R, Soler M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20: 73-8.
34. Ayres JG Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59: 701-8.
35. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115: 459-65.
36. MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158: 1438-45.
37. Togias A, Corren J, Shapiro G, et al. Anti-IgE treatment reduces skin test (ST) reactivity. J Allergy Clin Immunol 1998; 101: S171.
38. Saini SS, MacGlashan DW Jr, Sternisky SA, et al. Downregulation of human basophil IgE and FceRIa surface densities and mediator release by anti-IgE-infusion reversible in vitro and in vivo. J Immunol 1999; 162: 5624-30
39. Nopp A, Johansson SGO, Ankerst J, Palmqvist M, Öman H. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy 2007; 62: 1175-81
40. Nopp A, Johansson SGO, Adédoyin J, Ankerst J, Palmqvist M, Öman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2009; 65: 56-60.
41. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106 (2): 253-9.
42. Plewako H, Arvidsson M, Petruson K, et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002; 110: 68-71.
43. Kopp MV, Brauburger J, Riedinger F, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 110: 728-35.
44. Casale T, Condemi J, Miller SD, et al. RhuMAb-E25 in the treatment of seasonal allergic rhinitis (SAR). Ann Allergy Asthma Immunol 1999; 82: 75.
45. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitan allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59: 709-17.
46. Wenzel S. Severe asthma in adults Am J Respir Crit Care Med 2005; 172: 149-60.
47. Busse WW, Banks-Schiegel S,Wenzel S. Pathophysiology of severe asthma. J Allergy Clin Immunol 2000; 106: 1033-42.
48. Humbert M, Beaskey R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-6.
49. Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008; 102 (1): 71-6.
50. Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009; 103 (11): 1725-31.
51. Brusselle G, Michils A, Louis R, et al I. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103 (11): 1633-42.
52. Niven R. A UK survey of oral corticosteroid use in patients treated with omalizumab.Thorax 2007; 62 (Suppl 3): A98.
53. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy 2009; 39: 788-97
54. Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010 Feb 10 (Epub ahead of print).